Rixubis market to grow on hemophilia diagnosis and home therapy trends

The Business Research Company says the global Rixubis market is gaining momentum as hemophilia diagnosis improves, home infusion expands and demand rises for recombinant factor IX therapies. North America led the market in 2025, while Asia-Pacific is expected to post the fastest growth through 2035.

Why it matters: - Rixubis is a recombinant factor IX therapy used to treat and prevent bleeding episodes in hemophilia B, so market growth tracks the broader shift toward more specialized bleeding-disorder care. - The report points to stronger diagnosis rates, wider treatment access and better reimbursement as factors that could expand use of the therapy. - Growth in the market also reflects the push to reduce bleeding episodes and improve quality of life for patients with hemophilia B.

What happened: - The Business Research Company released its Rixubis Market Global Market Report 2026, covering market size, trends and forecasts for 2026-2035. - The report says the Rixubis market is drawing more attention as hemophilia diagnosis and treatment continue to evolve. - A free sample of the report is available here. - The full report is available here.

The details: - Past market growth has been driven by better hemophilia diagnosis, broader access to recombinant factor IX therapies, more specialized treatment centers, stronger patient education and favorable reimbursement policies. - Future growth is expected to come from long-acting clotting factors, more personalized hemophilia care, expanded home infusion services, improved recombinant manufacturing efficiency and efforts to minimize bleeding episodes. - Key trends include greater use of recombinant clotting factors, more prophylactic treatment, broader adoption of home-based therapy, stronger adherence programs and increased focus on patient quality of life. - Rixubis is designed to replace missing factor IX in people with hemophilia B and help control bleeding. - The report says increasing hemophilia cases worldwide are supporting demand, as more patients are diagnosed through advanced methods, higher awareness and population growth. - Pfizer reported that the diagnosed patient population with hemophilia A and B in the UK surpassed 11,800 between 2023 and 2024. - More clinical trials are also supporting the market by helping assess safety, efficacy and dosing for treatments like Rixubis. - Industry-sponsored clinical trials in the UK rose from 411 in 2022 to 426 in 2023, according to data from the Association of the British Pharmaceutical Industry. - Expanding healthcare R&D funding is another market tailwind. - The Congressional Research Service said US research and development funding is projected to reach $209.7 billion in fiscal 2024, up 4.4% from an estimated $200.8 billion the prior year. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 report package adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables.

Between the lines: - North America was the largest regional market in 2025, which suggests the therapy remains most established in markets with strong healthcare infrastructure and a larger treated patient base. - Asia-Pacific is expected to grow fastest during the forecast period, pointing to room for diagnosis expansion and improved access in a still-developing care environment. - The report’s emphasis on home infusion, adherence tools and prophylaxis signals a market moving beyond basic treatment access toward more convenient and preventive care models.

What's next: - The market outlook through 2035 depends on whether longer-acting clotting factors and home-based care gain wider adoption. - More diagnosis efforts and better access to specialized treatment centers should continue to shape demand across regions. - The report points to ongoing innovation in recombinant manufacturing and personalized hemophilia care as the next major growth levers. - More information is available from The Business Research Company through its report pages and social channels, including LinkedIn and LinkedIn.